Monday, 31 August 2026European Markets

JDE PEET'S Stock Bullish Momentum With A 12.59% Rise On Wednesday

Loading stream...

(VIANEWS) - The Market ended the session with JDE PEET'S (JDEP.AS) jumping 12.59% to €20.80 on Wednesday while AEX-Index rose 1.39% to €920.62.

JDE PEET'S's last close was €18.47, 33.51% under its 52-week high of €27.78.

About JDE PEET'S

JDE Peet's N.V., together with its subsidiaries, provides various coffee and tea products worldwide. It operates through LARMEA, APAC, Europe, and Peet's segments. The company sells its products under the L'OR, Peet's, Jacobs, Senseo, Tassimo, Douwe Egberts, OldTown, Super, Pickwick, and Moccona brand names. It serves various businesses, such as offices, hotels, bars, and restaurants, as well as coffee stores. JDE Peet's N.V. was founded in 1753 and is headquartered in Amsterdam, the Netherlands. JDE Peet's N.V. operates as a subsidiary of Acorn Holdings B.V.

Earnings Per Share

As for profitability, JDE PEET'S has a trailing twelve months EPS of €0.76.

PE Ratio

JDE PEET'S has a trailing twelve months price to earnings ratio of 27.37. Meaning, the purchaser of the share is investing €27.37 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.27%.

More news about JDE PEET'S (JDEP.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com